|
|
|
|
|
|
|
|
|
22.10.25 - 09:00
|
SINOPHARM Leaps 4%+; M Stanley Bets on Shr Price Rise in Next 30 Days (AAStocks)
|
|
|
SINOPHARM (01099.HK) reached a peak of HKD19.64 this morning. It last traded at HKD19.52, up 4.3%, with a trading volume of 8.426 million shares, involving HKD163 million.Morgan Stanley has published a strategic research report saying that SINOPHARM's stock price will have a 70-80% chance of rising within the next 30 days. A......
|
|
|
22.10.25 - 05:45
|
Research: M Stanley Estimates SINOPHARM to Rise in Next 30 Days (AAStocks)
|
|
|
Morgan Stanley wrote in its research report that SINOPHARM (01099.HK) will have a 70-80% chance of rising in the next 30 days. It gave the company an Overweight rating and a target price of HKD22.5.The report highlighted that two subsidiaries of SINOPHARM had announced their 3Q25 results, which showed a positive QoQ turnaround a......
|
|
|
26.08.25 - 06:15
|
Research: BofAS Adds SINOPHARM TP to $23, Reaffirms Rating at Buy (AAStocks)
|
|
|
SINOPHARM (01099.HK)'s 1H25 total revenue fell 2.9% YoY to RMB286 billion, BofA Securities issued a research report saying. Gross profit margin decreased from 7.4% in the same period last year to 7.1%, while net profit attributable to shareholders dropped by 6.4% YoY to RMB3.5 billion. In 2Q25, total revenue increased by -2.......
|
|
|
|
|
25.08.25 - 03:15
|
Results: SINOPHARM Interim NP RMB3.466B, Down 6.4%; Nil Div. (AAStocks)
|
|
|
SINOPHARM (01099.HK) announced its interim results for the six months ending June 30, 2025, reporting revenue of RMB286.043 billion, down 2.9% YoY. Net profit fell 6.4% YoY to RMB3.466 billion, with EPS of RMB1.11. No dividend was declared.~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
|
|
15.07.25 - 05:45
|
Research: M Stanley Cuts SINOPHARM TP to $22.5, Rating Overweight (AAStocks)
|
|
|
Morgan Stanley released a research report lowering its 2025-2030 earnings forecasts for SINOPHARM (01099.HK) by 1-6%, due to lower sales forecasts for the medical device and drug distribution segments. The broker cut its target price from $23 to $22.5, with rating at Overweight. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...
|
|
|
|
|
12.06.25 - 23:42
|
XFRA: DIVIDEND/INTEREST INFORMATION - 16.06.2025 - EQUBF_01 (XETRA)
|
|
|
Das Instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY wird cum Dividende/Zinsen gehandelt am 13.06.2025 und ex Dividende/Zinsen am 16.06.2025
The instrument X2S CNE100000FN7 SINOPHARM GRP CO. H YC 1 EQUITY has its pre-dividend/interest day on 13.06.2025 and its ex-dividend/interest day on 16.06.2025...
|
|
|
|
|
03.04.25 - 09:15
|
Research: HTSC Trims SINOPHARM TP to $22.54 as 2024 NP Misses (AAStocks)
|
|
|
SINOPHARM (01099.HK)'s 2024 revenue fell 2% YoY, while net profit dropped 22.1% YoY, both of which missed market consensus, Huatai Securities issued a research report saying.Looking ahead to 2025, Huatai Securities was optimistic about positive net profit growth of the Group, and kept rating at Buy, with its target price tri......
|
|
|
25.03.25 - 04:30
|
Research: CLSA: SINOPHARM FY2024 Earnings Miss; TP Dropped to $20 (AAStocks)
|
|
|
SINOPHARM (01099.HK)'s FY2024 revenue was broadly in line with market consensus, but earnings missed forecasts, mainly due to margin pressure and an one-off impairment of goodwill and intangible assets at Guoda Pharmacy, CLSA released a research report saying.The broker dropped its target price for SINOPHARM from $24.8 to $2......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
